PeterACohenMD

PubMed

• Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma.
  Trupti Vardam-Kaur, Latha B. Pathangey, Daniel J. McCormick, P. Leif Bergsagel, Peter A. Cohen, Sandra J. Gendler> ;Oncotarget. 2021 Sep 28
• 13 citations
  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide
  Nitin T. Supekar, Vani Lakshminarayanan, Chantelle J. Capicciotti, Anju Sirohiwal, Cathy S. Madsen, Margreet A. Wolfert, Peter A. Cohen, Sandra J. Gendler, Geert-Jan B...> ;Chembiochem. 2018 Jan 18
• 57 citations
  Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment.
  Aliyah M. Weinstein, Lu Chen, Emily A. Brzana, Prashanti R. Patil, Jennifer L. Taylor, Kellsye L. Fabian, Callen T. Wallace, Sabrina D. Jones, Simon C. Watkins, Binfen...> ;Oncoimmunology. 2017 Jun 6
• 121 citations
  Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
  Yana G. Najjar, Patricia Rayman, Xuefei Jia, Paul G. Pavicic, Brian I. Rini, Charles S. Tannenbaum, Jennifer S. Ko, Samuel Haywood, Peter A. Cohen, Thomas A. Hamilton,...> ;Clinical Cancer Research. 2017 May 1
• 10 citations
  Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cell...
  Latha B. Pathangey, Dustin B. McCurry, Sandra J. Gendler, Ana Lucia Dominguez, Jessica E. Gorman, Girish Pathangey, Laurie A. Mihalik, Yushe Dang, Mary L. Disis, Peter...> ;Oncotarget. 2017 Feb 14
• 9 citations
  Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet.
  Cheryl E. Myers, Dominique B. Hoelzinger, Tiffany N. Truong, Lindsey A. Chew, Arpita Myles, Leena Chaudhuri, Jan B. Egan, Jun Liu, Sandra J. Gendler, Peter A. Cohen> ;Oncotarget. 2017 Jan 11
• 17 citations
  Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists
  Soraya Zorro Manrique, Ana Lucia Dominguez, Noweeda Mirza, Christopher D. Spencer, Judy M. Bradley, James H. Finke, James J. Lee, Larry R. Pease, Sandra J. Gendler, Pe...> ;Oncotarget. 2016 Jun 21
• 40 citations
  MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
  Vani Lakshminarayanan, Nitin T. Supekar, Jie Wei, Dustin B. McCurry, Amylou C. Dueck, Heidi E. Kosiorek, Priyanka Trivedi, Judy M. Bradley, Cathy S. Madsen, Latha B. P...> ;Plos One. 2016 Jan 20
• 30 citations
  Late Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)
  Gregory N. Dietsch, Tressa D. Randall, Raphael Gottardo, Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Kristi Manjarrez, Mona Newkirk, James Kyle Bryan, R...> ;Clinical Cancer Research. 2015 Dec 15
• 32 citations
  Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide
  Pamela Thompson, Vani Lakshminarayanan, Nitin T. Supekar, Judy M. Bradley, Peter A. Cohen, Margreet A. Wolfert, Sandra J. Gendler, Geert-Jan Boons> ;Chemical Communications. 2015 Jun 9
• 37 citations
  Inhibition of Adaptive Immunity by IL9 Can Be Disrupted to Achieve Rapid T-cell Sensitization and Rejection of Progressive Tumor Challenges
  Dominique B. Hoelzinger, Ana Lucia Dominguez, Peter A. Cohen, Sandra J. Gendler> ;Cancer Research. 2014 Dec 1
• 39 citations
  A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
  Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Daniel D. Von Hoff, Glen J. Weiss, Gregory N. Dietsch, Kristi Manjarrez, Tressa D. Randall, Robert M. Hershberg> ;Clinical Cancer Research. 2014 Jul 15
• 53 citations
  Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist
  Abu-Baker M. Abdel-Aal, Vani Lakshminarayanan, Pamela Thompson, Nitin T. Supekar, Judy M. Bradley, Margreet A. Wolfert, Peter A. Cohen, Sandra J. Gendler, Geert-Jan Boons> ;Chembiochem. 2014 Jul 7
• 162 citations
  Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
  Thinle Chodon, Begonya Comin-Anduix, Bartosz Chmielowski, Richard C. Koya, Zhongqi Wu, Martin Auerbach, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Ta...> ;Clinical Cancer Research. 2014 May 1
• 35 citations
  Combination of sunitinib with anti‐tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy
  Ritika Jaini, Patricia Rayman, Peter A. Cohen, James H. Finke, Vincent K. Tuohy> ;International Journal of Cancer. 2014 Apr 1
• 12 citations
  Downregulation of Hematopoietic MUC1 during Experimental Colitis Increases Tumor-Promoting Myeloid-Derived Suppressor Cells
  Tze Wei Poh, Cathy S. Madsen, Jessica E. Gorman, Ronald J. Marler, Jonathan A. Leighton, Peter A. Cohen, Sandra J. Gendler> ;Clinical Cancer Research. 2013 Sep 15
• 39 citations
  Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.
  James H. Finke, Pat Rayman, Jennifer S. Ko, Judy M. Bradley, Sandra J. Gendler, Peter A. Cohen> ;Cancer Journal. 2013 Jul 1
• 62 citations
  A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Ce...
  Lisa A. Kottschade, Vera J. Suman, Domingo G. Perez, Robert R. McWilliams, Judith S. Kaur, Thomas Amatruda, Francois J. Geoffroy, Howard M. Gross, Peter A. Cohen, Anth...> ;Cancer. 2013 Feb 1
• 21 citations
  Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17.
  Christopher Paustian, Patricia Taylor, Terrence Johnson, Min Xu, Nancy Ramirez, Ken S. Rosenthal, Suyu Shu, Peter A. Cohen, Brian J. Czerniecki, Gary K. Koski> ;Plos One. 2013 Jan 31
• 28 citations
  Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologi...
  Peter A. Cohen, Jennifer S. Ko, Walter J. Storkus, Christopher D. Spencer, Judy M. Bradley, Jessica E. Gorman, Dustin B. McCurry, Soroya Zorro-Manrique, Anna Lucia Dom...> ;Immunological Investigations. 2012 Sep 27
• 34 citations
  Vaccines Targeting Tumor Blood Vessel Antigens Promote CD8+ T Cell-Dependent Tumor Eradication or Dormancy in HLA-A2 Transgenic Mice
  Xi Zhao, Anamika Bose, Hideo Komita, Jennifer L. Taylor, Nina Chi, Devin B. Lowe, Hideho Okada, Ying Cao, Debabrata Mukhopadhyay, Peter A. Cohen, Walter J. Storkus> ;Journal of Immunology. 2012 Feb 15
• 221 citations
  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
  Vani Lakshminarayanan, Pamela Thompson, Margreet A. Wolfert, Therese Buskas, Judy M. Bradley, Latha B. Pathangey, Cathy S. Madsen, Peter A. Cohen, Sandra J. Gendler, G...> ;Proceedings of the National Academy of Sciences of the United States of America. 2012 Jan 3
• 112 citations
  Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination
  Anamika Bose, Jennifer L. Taylor, Sean Alber, Simon C. Watkins, Jorge A. Garcia, Brian I. Rini, Jennifer S. Ko, Peter A. Cohen, James H. Finke, Walter J. Storkus> ;International Journal of Cancer. 2011 Nov 1
• 217 citations
  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
  James H. Finke, Jennifer S. Ko, Brian I. Rini, Pat Rayman, Joanna Ireland, Peter A. Cohen> ;International Immunopharmacology. 2011 Jul 1
• Lenalidomide following rituximab and fludarabine in untreated CLL.
  Ujjani CS, Jamshed S, Fitzpatrick KW, Gehan EA, Crawford J, Broome CM, Cohen P, Kessler C, Cheson BD> ;J. Clin. Oncol.. 2011-05-20
• Join now to see all